EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy

Janice A Layhadi, Liliana Cifuentes Gutierrez, Sean T Keane, William Fulton iD, Nichell A Samson, Lily Y D Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez-Gil, Stephen R Durham iD, Guy Scadding and 5 more

Allergy · 2026-06 · 81 (6) · 2156-2171

DOI: 10.1111/all.70280 ↗

At a glance

Journal article in Allergy, published online on 2026-03-19. Written by Janice A Layhadi and 16 co-authors. Institution: National Heart and Lung Institute, Imperial College London, London, UK. Major MEDLINE topics: Glycoproteins, Desensitization, Immunologic, Allergens, Hypersensitivity. Cited 1 times so far (Crossref); 76 references. The full text is freely available (open access, CC BY 4.0). Funded by: Angany Inc., Canada.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Allergen immunotherapy (AIT) is the only disease‐modifying therapeutic approach for cat allergy, though it requires at least three years of treatment and can potentially induce severe systemic reactions. Plant‐derived bioparticles expressing Fel d 1 allergen (Fel d 1 e BP) have been developed as a novel therapeutic candidate for cat allergy. We aimed to investigate the allergenicity and immunogenicity profile of Fel d 1 e BP.

Methods

Fel d 1 e BP was synthesised in vivo in Nicotiana benthamiana and confirmed by cryo‐electron microscopy and tomography. Immune modulatory properties of purified natural Fel d 1 (nFel d 1) and Fel d 1 e BP were assessed at T and B cells by flow cytometry in 12 cat‐allergic subjects (CA) and 12 non‐atopic controls (NAC). Single‐cell RNA‐seq was used to assess molecular mechanisms of Fel d 1 e BP immune skewing. The safety of Fel d 1 e BP was assessed by measuring basophil responsiveness in whole blood and further confirmed in vivo by its administration as a skin prick test (SPT) in 20 cat‐allergic individuals.

Results

Fel d 1 e BP was shown to be a strong inducer of Th1 cells ( p < 0.05) and IL‐10 + non‐Th2 cells ( p < 0.05) in CA subjects. Fel d 1 e BP showed a stronger trend for inducing IL‐10 + Breg cells compared to nFel d 1, peaking at 3 μg/mL. scRNA‐seq analyses demonstrated that Fel d 1 e BP targets the induction of protective metallothionein genes, CCL18 + monocytes and naïve B cells that are interferon responsive and metabolically activated. Moreover, Fel d 1 e BP demonstrated reduced capacity to elicit basophil activation ( p < 0.001) and histamine release ( p < 0.01), indicating their hypoallergenic nature. Administration of titrated doses of Fel d 1 e BP through skin prick test revealed that they are well‐tolerated with reduced mean wheal compared to native Fel d 1 in an open‐label Phase 0 study (all, p < 0.001).

Conclusions

We demonstrate that Fel d 1 e BP is hypoallergenic and demonstrates tolerogenic properties, making it a novel candidate for use in AIT for cat allergy.

Subjects

MeSH terms (MEDLINE)

GlycoproteinsDesensitization, ImmunologicAllergensHypersensitivityAnimalsHumansCatsFemaleMalePlants, Genetically ModifiedAdultNicotianaImmunoglobulin ESkin TestsBasophilsCytokines

Author keywords

allergen immunotherapyallergycat allergytolerance induction

Substances

GlycoproteinsAllergensFel d 1 protein, Felis domesticusImmunoglobulin ECytokines

Authors and institutions

  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Angany Inc., Lévis, Quebec, Canada.
  • Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Institute for Infection and Immunity, Inflammatory Diseases, Amsterdam, the Netherlands.

ORCID profiles: William Fulton, Stephen R Durham

Funding

  • Angany Inc., Canada

Cite

APA

Layhadi, J. A., Gutierrez, L. C., Keane, S. T., Fulton, W., Samson, N. A., Wu, L. Y. D., Filipaviciute, P., Hikmawati, P., Fedina, O., Jimenez-Gil, A., Durham, S. R., Scadding, G., Tropper, G., Vézina, L. P., Colin, P., van Ree, R., & Shamji, M. H. (2026). Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy. Allergy, 81(6), 2156-2171. https://doi.org/10.1111/all.70280

Vancouver

Layhadi JA, Gutierrez LC, Keane ST, Fulton W, Samson NA, Wu LYD, et al. Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy. Allergy. 2026;81(6):2156-2171. doi:10.1111/all.70280

BibTeX
@article{Layhadi2026,
  author = {Layhadi, Janice A and Gutierrez, Liliana Cifuentes and Keane, Sean T and Fulton, William and Samson, Nichell A and Wu, Lily Y D and Filipaviciute, Paulina and Hikmawati, Prista and Fedina, Oleksandra and Jimenez-Gil, Ana and Durham, Stephen R and Scadding, Guy and Tropper, Guy and Vézina, Louis-Philippe and Colin, Patrick and van Ree, Ronald and Shamji, Mohamed H},
  title = {Fel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {6},
  pages = {2156--2171},
  doi = {10.1111/all.70280}
}
Start for free →